ArticleBlood2025

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Pedro Vianna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.